**Core tip:** Treatment of advanced hepatocellular carcinoma still represents an unmet medical need. Novel therapeutic options comprise new tyrosine kinase inhibitors, epigenetic modifiers and increasingly also cell therapy and immune checkpoint inhibitors and combinations of those modalities. Development of better drugs is closely linked to improved preclinical and animal models and has to be accompanied by the implementation of predictive biomarkers, which is still lacking for hepatocellular carcinoma. The current status of these aspects is reviewed in this manuscript.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, accounting for approximately 85% of all cases. It is considered to be the 6^th^ most commonly diagnosed cancer and the 4^th^ most common cause of cancer related death worldwide, with 2 to 3 times higher rates for men\[[@B1]\]. Major risk factors are chronic viral hepatitis \[hepatitis B virus (HBV) and hepatitis C virus (HCV)\], aflatoxin exposure, alcohol intake, and the globally increasing high rates of obesity and type 2 diabetes\[[@B2]\]. The 5-year survival rate of advanced HCC remains devastating at 1% and is the poorest of all solid cancers\[[@B3]\]. Treatment of advanced stages of HCC is often limited by the underlying liver disease which is commonly accompanied by cirrhosis and end-stage liver disease with significantly impaired liver function. Due to those different etiologies and pathogenetic mechanisms, the identification of common oncogenic drivers is challenging although heterogeneous sets of mutations could be detected in HCC (Table [1](#T1){ref-type="table"}), of which especially telomerase, p53, β-catenin and others were linked to distinct and prognostic HCC subtypes (Table [2](#T2){ref-type="table"})\[[@B4],[@B5]\].

###### 

Known dysregulated pathways and genes in hepatocellular carcinoma with mode of action and frequency (modified from\[[@B4],[@B5],[@B92]\])

  **Pathways / genes**                                                                         **Alteration**                    **Frequency in HCC**
  -------------------------------------------------------------------------------------------- --------------------------------- ----------------------
  AKT-mTOR-MAPK signaling                                                                                                        
  RPS6KA3                                                                                      Mutation                          2%%-9%
  TSC1 and TSC2                                                                                Mutation or deletion              3%-8%
  PTEN                                                                                         Mutation or deletion              1%-3%
  FGF3, FGF4 and FGF19                                                                         Amplification                     4%-6%
  PI3KCA                                                                                       Mutation                          0%-2%
  Angiogenesis                                                                                                                   
  VEGFA                                                                                        Amplification                     3%-7%
  Antioxidation                                                                                                                  
  NFE2L2 KEAP1                                                                                 Mutation Mutation                 3%-6% 2%-8%
  Cell cycle control/tumor suppressors                                                                                           
  TP53\*                                                                                       Mutation or deletion              12%-45%
  RB1                                                                                          Mutation or deletion              3%-8%
  CCND1\*                                                                                      Amplification                     5%-14%
  Epigenetic and chromatin remodeling                                                                                            
  ARID1A\*                                                                                     Mutation or deletion              4%-17%
  ARID2\*                                                                                      Mutation                          3%-18%
  BAP1                                                                                         Mutation                          5%\[[@B117]\]
  Immortalization/telomere maintenance                                                                                           
  ERT\*                                                                                        Promotor mutation amplification   54%-60% 5%-6%
  JAK/STAT                                                                                                                       
  JAK1                                                                                         Mutation                          5%
  Metabolic pathways                                                                                                             
  Afamin apoptogenic protein 1, mitochondrial                                                  Mutation                          Up to 10%\[[@B117]\]
  Oncogenes                                                                                                                      
  MET\*                                                                                        Amplification                     30%-50%
  MYC                                                                                          Amplification                     4%
  TGFβ pathway                                                                                                                   
  Osteopontin                                                                                  Mutation                          Up to 40%\[[@B118]\]
  G2/mitotic-specific cyclin-B2 Cyclin-dependent kinase 1 lymphoid enhancer-binding factor 1                                     
  Integrin α2                                                                                                                    
  Wnt pathway                                                                                                                    
  Catenin β1\*                                                                                 Mutation                          11%-37%
  AXIN1\*                                                                                      Mutation or deletion              5%-15%

HCC: Hepatocellular carcinoma.

###### 

Summary of classification schemes of hepatocellular carcinoma (modified from\[[@B119]\])

  **First author**                                                              **Lee et al\[[@B120]\]**   **Boyault et al\[[@B121]\]**   **Chiang et al\[[@B122]\]**   **Hoshida et al\[[@B123]\]**   **Désert et al\[[@B124]\]**   **TCGA network\[[@B117]\]**
  ----------------------------------------------------------------------------- -------------------------- ------------------------------ ----------------------------- ------------------------------ ----------------------------- -----------------------------
  Year                                                                          2004                       2006                           2008                          2009                           2017                          2017
  HCC cases                                                                     91                         56                             91                            232                            1133                          559
  Number of subgroups                                                           2                          6                              5                             3                              4                             3
  Names of classes                                                              Cluster A/B                G1-G6                          CTNNB1-proliferation          S1-S3                          PP, PV, ECM, STEM             iCluster1-iCluster3
  Major applied technology for molecular profiling                                                                                                                                                                                   
  Transcriptomics                                                               X                          X                              X                             X                              X                             X
  Genetic Mutations                                                                                        X                                                                                                                         X
  Copy number alterations                                                                                                                 X                                                                                          X
  Metabolomics                                                                                                                                                                                         X                             
  Epigenomics                                                                                              X (CDH1 and CDKN2A)                                                                                                       X
  Proteomics                                                                                                                                                                                                                         X
  Major HCC Classes with clinic-pathological features and high mutation rates                                                                                                                                                        
  **Proliferative phenotype**                                                                                                                                                                                                        
  Poor outcome                                                                  A                          G1, G2, G3                     Proliferation                 S1 + S2                        ECM + STEM                    iCluster 1 + 3
  High AFP                                                                                                                                                                                                                           
  Moderate to poor differentiation                                                                                                                                                                                                   
  P53                                                                                                                                                                                                                                
  **Non-proliferative phenotype**                                                                                                                                                                                                    
  Good to moderate outcome                                                      B                          G5, G6                         CTNNB1                        S3                             PP + PV                       iCluster 2
  Low AFP                                                                                                                                                                                                                            
  CTNNB1                                                                                                                                                                                                                             

ECM: Extracellular matrix; PP: Periportal; PV: Perivenous; STEM: Stem/progenitor cells; HCC: Hepatocellular carcinoma.

Curative therapy is currently only possible in early stages by complete surgical resection or orthotopic liver transplantation, the latter being limited by availability of donor organs. Locoregional therapies \[*e.g*., transarterial chemoembolization (TACE), different ablation strategies, selective internal radiotherapy (SIRT)\] are available for intermediate stages or HCCs not amenable to surgical therapy and can be applied repeatedly also for downstaging in preparation of transplantation or in an adjuvant setting prior to surgery\[[@B6],[@B7]\]. In addition, external beam radiation (EBRT) is a valuable adjuvant therapy option for small HCCs, in combination with surgery or other locoregional therapies or as a bridging option to orthotopic liver transplantation. It can also help to reduce pain in extrahepatic metastases and prolong survival after surgical resection\[[@B8]\]. For further details on locoregional and non-systemic treatment options, we refer the reader to a recent meta-analysis on the management of HCC\[[@B9]\].

Since the introduction of the multi-kinase inhibitor sorafenib about a decade ago, only little progress has been made in treatment of advanced HCC. In this article, we will review the current status of novel drugs for the treatment of advanced HCC including the emerging immune checkpoint inhibitor therapies. We will also highlight recent trends in identifying predictive biomarkers and establishing animal models that closely resemble the complex and diverse human pathophysiology of HCC.

CONVENTIONAL CHEMOTHERAPY AND MOLECULAR TARGETED THERAPIES
==========================================================

Prior to the approval of sorafenib, no standard chemotherapy regimen had been established for treatment of advanced HCC. Randomized trials and meta-analyses showed a poor response rate of different agents like 5-fluorouracil (5-FU), cisplatin, doxorubicin or hormonal therapy (*e.g*., tamoxifen or somatostatin-analogues). The high intrinsic resistance of HCC is considered due to the high expression of efflux pumps (linked to the physiologic metabolic capacity of the liver parenchyma), altered blood flow and fibrosis as well as high expression and mutations in drug resistance genes like p53. Most tested drugs showed only modest activity with minimal improvement in overall survival but with significant toxicities in combination\[[@B6],[@B10]\].

The small-molecule multi-kinase inhibitor sorafenib was the first drug to show an overall survival benefit in first-line therapy of advanced HCC (10.7 mo *vs* 7.9 mo; 6.5 mo *vs* 4.2 mo in Asian patients) in randomized controlled trials\[[@B11],[@B12]\]. Since then, only lenvatinib was able to achieve increased overall survival (in a phase 2 study) and was proven to be non-inferior to sorafenib in a recent phase 3 study, reaching a median survival time of 13.6 mo compared to 12.3 mo for sorafenib\[[@B13],[@B14]\].

Similarly, results for new drugs in a second-line setting after failure of sorafenib were mostly disappointing. Regorafenib, a derivative of sorafenib, and the novel multi-kinase inhibitor cabozantinib achieved a significant increase in overall survival in placebo-controlled trials. Regorafenib increased overall survival to 10.6 mo *vs* 7.8 mo\[[@B15]\], while cabozantinib achieved overall survival of 10.2 mo *vs* 8.0 mo with toxicity similar to regorafenib\[[@B16]\]. Lately the vascular endothelial growth factor receptor 2 (VEGFR-2) antibody ramucirumab proved efficacy in sorafenib pretreated patients with an alpha-fetoprotein level of ≥ 400 mg/mL\[[@B17]\]. The randomized phase-III placebo controlled trial REACH-2 showed median overall survival times of 8.5 mo for ramu-cirumab treated patients *vs* 7.3 mo for the placebo arm \[hazard ratio (HR) = 0.7; *P* \< 0.0001\]. This is the first study to show a significant survival benefit for a bio-marker (alpha-fetoprotein) selected subgroup of HCC.

Several other targets for inhibition of receptor tyrosine kinase function in HCC were investigated. Hepatocyte growth factor (HGF) and its receptor c-Met are com-monly overexpressed in HCC and have been linked to poor prognosis and re-sistance to *e.g*., sorafenib treatment\[[@B18]-[@B20]\]. c-Met is targeted by several multi-kinase inhibitors like gefitinib or cobazitinib and more recently also selective inhibitors like capmatinib or tepotinib entered clinical trials but results for studies in HCC are still pending\[[@B21]-[@B23]\]. Other less selective compounds with c-Met inhibition properties like crizotinib, brivanib or foretinib did not lead to significant prolongation of overall survival (OS) in phase III studies or were not investigated in HCC patients yet\[[@B21],[@B22],[@B24],[@B25]\].

All of these compounds are recommended for patients with preserved liver function, *i.e*., Child-Pugh score 5, 6 and 7\[[@B26]\]. Treatment options for patients with more advanced liver impairment or cirrhosis are still lacking and represent an urgent medical need. Esp. the use of sorafenib in patients with portal vein tumor thrombosis (PVTT) remains controversial\[[@B27]\]. In a study with 30 patients with advanced HCC and PVTT treated with sorafenib monotherapy, a disease control rate of 33.3% was achieved, including thrombus revascularization in a small number of patients. Yet, OS and progression-free survival (PFS) still remained disappointing with only 3.1 and 2.0 mo, respectively\[[@B28]\]. In combination with TACE, sorafenib was able to induce a significant survival benefit compared to TACE only in patients with type B (13 mo *vs* 6 mo) or type C (15 mo *vs* 10 mo) in a stud enrolling 99 patients\[[@B29]\]. Similar results were obtained in combination with radiofrequency ablation (RFA)\[[@B30]\]. Still, prospective randomized controlled trials on sorafenib or regorafenib monotherapy in this setting are missing and the effect of the combination approach is probably overruling the currently available results\[[@B27]\].

Different combination studies of sorafenib and other agents have been performed. Interestingly, vitamin K was shown to enhance the antitumor effects of sorafenib *via* reduction of expression of des-γ-carboxy prothrombin (DCP), a proangiogenic growth factor that can also trigger signaling *via* c-Met and which is commonly upregulated after sorafenib treatment\[[@B31],[@B32]\].

Combination studies with other targeted agents showed only a modest increase in survival but had significant increase in drug related adverse events or even showed a worse outcome than single agents like the sorafenib/erlotinib combination\[[@B33]\]. These agents have also been investigated in earlier disease stages but could not demonstrate a survival benefit in combination with locoregional approaches like TACE or in an adjuvant setting\[[@B7]\].

In summary, sorafenib and lenvatinib are options for first-line therapy of advanced HCC, while regorafenib, cabozantinib and ramucirumab can be used as second-line options afterwards.

IMMUNE CHECKPOINT INHIBITORS AND NOVEL IMMUNOTHERAPY TARGETS IN HCC
===================================================================

The development of immune checkpoint inhibitors like anti-CTLA4 (ipilimumab, tremelimumab) or anti-PD-1/PD-L1 (nivolumab, pembrolizumab, tislelizumab, camrelizumab, atezolizumab, durvalumab, avelumab) antibodies has dramatically changed clinical oncology nowadays and achieved sustained treatment responses in an unprecedented manner across different cancer types. Chronic inflammation due to the various underlying etiologies is a mainstay of HCC development. Different immune cell subtypes (T cells, macrophages, Kupffer cells) are currently intensively investigated to understand their role in HCC pathogenesis and to exploit them as novel and specific therapeutic approaches for this disease. Kupffer cells and CD8+ T cells in HCC have been shown to express high levels of PD-1 and PD-L1, thus playing a key role in the immune evasive phenotype of HCC. High expression of PD-L1 on tumor cells was associated with poorer outcome in HCC patients\[[@B34]-[@B37]\].

Several immune checkpoint inhibitors are currently investigated in clinical trials as single agents or in combination with neo-epitope releasing locoregional therapies, epigenetic drugs or conventional targeted agents\[[@B38]\].

In a phase 1 study, tremelimumab reached a clinical disease control rate of 76.4% with 17.6% of patients achieving partial response\[[@B39]\]. In combination with subtotal radiofrequency ablation or chemoablation, 26.3% of patients reached partial response and a median overall survival of 12.3 mo. Responders also showed increased infiltration of CD8+ T cells and HCV positive patients had a significant reduction in viral load\[[@B40]\].

Based on positive results of the phase 1/2 CheckMate-040 study, nivolumab received FDA approval as a 2^nd^ line therapy option in HCC\[[@B41]\]. An objective response rate of 20% was reached overall, and patients expressing PD-L1 on tumor cells even reached 26%. A subgroup analysis revealed disease control rates of up to 75% and a median duration of response of 9.9 mo. Results of the phase 3 CheckMate-459 study that compares nivolumab *vs* sorafenib are still pending.

Similar results were obtained for pembrolizumab in the KEYNOTE-224 study. Here, 17% of patients had partial response, 44% had stable disease and overall 77% of responding patients had durable responses of 9 mo or more. Pembrolizumab also received FDA approval as a 2^nd^ line therapy after sorafenib therapy.

Several further studies are currently ongoing to evaluate these checkpoint inhibitors in first or second line therapy of HCC, including the HIMALAYA study that explores durvalumab alone or in combination with tremelimumab *vs* sorafenib or the IMbrave50 study that combines atezolizumab with bevacizumab *vs* sorafenib\[[@B42]\].

Due to its physiologic role in clearing portal vein blood flow from potentially harmful gut content, the liver is a key immunologic organ and contains a high proportion of macrophages (Kupffer cells) and other cells of lymphoid lineage, including B and T cells as well as natural killer (NK) and NKT cells\[[@B43]\]. As outlined above, HCC commonly develops on the basis of chronic inflammatory liver injury and exploiting the immunologic repertoire of the liver. The first promising results of immune checkpoint inhibitors in HCC further support this approach. Different technologies have been developed to apply an adaptive cell transfer as a therapeutic option also in HCC, including application of tumor infiltrating lymphocytes, cytokine induced killer cells or fostering neoepitope release by locoregional ablation techniques\[[@B44]-[@B46]\].

Recently, chimeric antigen receptor-engineered T (CAR-T) cells yielded outstanding responses in hematologic malignancies and received FDA approval for the treatment of acute lymphoblastic leukemia\[[@B47],[@B48]\] and diffuse large B-cell lymphoma\[[@B49],[@B50]\]. In brief, T cells of patients are harvested, genetically modified, expanded and reinfused into the patient. CARs consist of an extracellular antigen recognition domain, a hinge/spacer domain, a transmembrane domain and a T cell activation domain (CD3ζ). CARs of the 2^nd^ and 3^rd^ generation have additional costimulatory molecules like CD27 or CD134 in between the transmembrane and the CD3ζ domain to achieve prolonged T cell expansion and antitumor effects\[[@B51]\]. Success of CAR-T cells in solid tumors is limited by their broader mutational load compared to hematologic malignancies and suitable tumor antigens are thus more difficult to identify. An additional hurdle is the localization of modified T cells to the tumor, which is influenced by tumor angiogenesis, low levels of chemokines to attract T cells into the tumor and, esp. in HCC, a tumor microenvironment (stroma, fibrosis) that does not permit sufficient tissue penetration of large molecules\[[@B52]\]. The latter can be overcome by selective local administration like hepatic artery infusion which makes HCC an interesting option for this therapy approach and several studies using CAR-T cells were therefore initiated in HCC\[[@B44],[@B53]\] (Table [3](#T3){ref-type="table"}). Interestingly, most studies use the cell surface glycoprotein glypican-3 (GPC3) as an antigen, which is highly expressed in HCC but not in other adult tissues and has been linked to poor prognosis of HCC\[[@B54],[@B55]\]. Preclinically, CAR-T cells targeting GPC3 were able to eliminate HCC cells and prolong survival of tumor-bearing mice\[[@B56],[@B57]\]. Ongoing studies also evaluate different application routes like hepatic artery infusion, systemic infusion or combination with transarterial (chemo-)embolization and the effect of lymphodepleting conditioning. Preliminary results from study NCT02395250 indicate that GPC3-CAR-T cells are safe in relapsed or refractory Chinese HCC patients. In this study, 1 partial response and 2 stable diseases were observed as best response (from 6 evaluable patients), all durable for more than one year\[[@B58]\].

###### 

Clinical trials with chimeric antigen receptor T cells cells in hepatocellular carcinoma

  **NCT**                                       **Antigen**   **Phase**   **Patients**   **Sponsor**   **Status**           **Comments**
  --------------------------------------------- ------------- ----------- -------------- ------------- -------------------- -----------------------
  NCT02715362                                   GPC3          I/II        30             Company       Recruiting           HAI
  NCT03672305                                   c-Met/PD-L1   I           50             Academic      Not yet recruiting   IV
  NCT02723942                                   GPC3          I/II        60             Academic      Completed            
  NCT03198546                                   GPC3          I           30             Academic      Recruiting           
  NCT02395250                                   GPC3          I           13             Academic      Completed            \[[@B58]\]
  NCT03349255                                   AFP           I           18             Company       Recruiting           IV *vs* HAI
  NCT03130712                                   GPC3          I/II        10             Company       Recruiting           IT
  NCT03084380                                   GPC3          I/II        20             Academic      Not yet recruiting   Combination with TACE
  NCT02905188[1](#T3FN1){ref-type="table-fn"}   GPC3          I           14             Academic      Not yet recruiting   
  NCT03302403                                   GPC3          I           48             Academic      Not yet recruiting   
  NCT03146234                                   GPC3          I           20             Academic      Recruiting           
  NCT01935843                                   Her2          I/II        10             Academic      Unknown              
  NCT02959151                                   GPC3          I/II        20             Company       Unknown              
  NCT02587689                                   MUC1          I/II        20             Company       Unknown              
  NCT03013712                                   EpCAM         I/II        60             Academic      Recruiting           

Location of study is United States, all other trials are conducted in China. HAI: Hepatic artery infusion; IT: Intratumoral injection; IV: Intravenous injection; TACE: Transarterial chemoembolization.

EPIGENETIC THERAPY WITH HDAC INHIBITORS IN HCC
==============================================

Epigenetic dysregulation of gene activity is essentially involved in HCC tumorigenesis as evidenced by dysregulation of histone deacetylases *in vitro*, *in vivo* and *in situ*\[[@B59],[@B60]\]. Treatment with HDAC inhibitors (HDACi) therefore represents an attractive therapeutic option in liver cancer that addresses different molecular mechanisms compared to chemotherapy or targeted therapies to inhibit tumor cell growth and promote cell death. HDACi inhibitors commonly inhibit cell cycle progression by reexpression of p21^cip1/waf1^ in a p53-dependent manner but can also mediate alternative cell death pathways like unfolded protein response and ER stress pathways due to their non-specific acetylation of proteins also outside the nucleus\[[@B61]-[@B65]\]. Although some case reports showed a positive effect of HDACi in com-bination with sorafenib in HCC\[[@B66]\], most studies are disappointing so far. A phase 2 study using belinostat (inhibitor of all zinc dependent HDAC isoforms) in unresectable HCC showed a PFS and OS of 2.6 and 6.6 mo, respectively\[[@B67]\]. The SHELTER study investigated resminostat (oral pan-HDACi with predominant activity against HDAC1, 2 and 3) in combination with sorafenib in a 2^nd^ line setting of advanced HCC and demonstrated an OS of 8.0 mo, while monotherapy resminostat reached only 4.1 mo\[[@B68]\]. Interestingly, this combination was also used in a 1^st^ line setting in Asian patients but did not provide evidence for an OS benefit over sorafenib\[[@B69]\].

These studies, like others investigating tyrosine kinase inhibitors, usually enroll patients with progressive, unresectable, locally advanced or metastatic HCC with an overall poor prognosis that limits the chance of achieving PFS or OS advantages\[[@B70]\]. Yet, epigenetic therapies may be able to overcome such hurdles and even enhance the results of immune checkpoint inhibitors in HCC. Epigenetic targeting with the enhancer of zeste homolog 2 (EZH2), a histone-lysine-N-methyltransferase, inhibitor 3-Deazaneplanocin A (DZNep) and the DNA methyltransferase 1 (DNMT1) inhibitor 5-azacytidine reactivated transcriptionally repressed chemokines genes and augmented T cell trafficking to the tumor\[[@B71]\]. Consequently, epigenetic pretreatment may lead to priming of so-called immune cold tumors also in HCC\[[@B71],[@B72]\].

NOVEL BIOMARKERS TO IMPROVE PATIENT OUTCOME
===========================================

HCC patients are commonly stratified based on their liver function capacity as assessed by Child-Pugh score, which overall seems to be a better predictor for treatment outcome than the underlying etiology of HCC\[[@B70],[@B73]\]. Biomarkers that could predict treatment response are therefore urgently needed, esp. for targeted therapies and immunotherapy approaches\[[@B74]\].

In a recent biomarker analysis of the sorafenib phase 3 STORM trial (BIOSTORM), none of the biomarkers related to angiogenesis or cell proliferation or other molecular markers like gene signatures or mutations could predict a treatment benefit or recurrence-free survival (RFS). Only p-ERK and microvascular invasion were associated with poor RFS. This study proposed a new 146-gene signature that identified about 30% of patients which benefit from sorafenib treatment. Interestingly, those patients were also enriched in CD4+ T and B cells, NK cells and were associated with signature of poor response to immune checkpoint inhibitors\[[@B75]\].

Analysis of the regorafenib phase 3 study in HCC (RESORCE), also recently identified a plasma protein expression profile \[angiopoietin 1, cystatin B, oxidized low density lipoprotein (LDL) receptor 1, latency associated peptide of transforming growth factor β (TGF-β) and macrophage inflammatory protein 1α (MIP1α)\] and 9 plasma miRNAs that were associated with increased overall survival and time to progression. The proposed soluble plasma protein biomarkers are also known to play a role in inflammation and HCC pathogenesis. Interestingly, none of these predictive biomarkers was so far shown to have prognostic relevance\[[@B76]\].

Overall, the identification and validation of biomarkers in HCC was previously limited by the availability of tissue specimens as international guidelines did not mandate a biopsy sample for diagnostic purposes. Recently, guidelines from EASL recommend taking tissue and liquid biopsies from HCC patients participating in clinical studies which could improve this situation\[[@B77]\]. Biomarker analyses in HCC are often limited by small sample size in respective subgroup analyses due to the diverse etiologic backgrounds like viral hepatitis, NASH/NAFLD, cirrhosis status etc. which all significantly impact on the underlying chronic inflammation or have direct influence on oncogenic pathways.

Numerous new diagnostic and prognostic biomarkers like GPC-3 or c-Met have been proposed recently and were also translated into CAR-T cell based therapy approaches (see above) but no clear predictive biomarker for either targeted therapies or for immune checkpoint inhibitors is available so far\[[@B78],[@B79]\].

Liquid biopsies are capable of detecting genetic and epigenetic alterations as well as expression patterns of DNA, RNA and miRNA from circulating tumor cells, cell-free nucleic acids or from exosomes. Success rate of these technologies is still variable depending on tumor size and stage but with further technological advances, *e.g*., on next generation sequencing from cell-free DNA, it is rapidly maturing to clinical applicability\[[@B80]-[@B82]\].

Assessment of metabolic pathways including proteomics and glycomics could further contribute to biomarker development although current approaches, *e.g*., detection of CD44v9\[[@B83]\] or Hippocalcin-like 1 (HPCAL1)\[[@B84]\], are used for diagnostic or prognostic settings or to predict disease recurrence and have not been linked to treatment responses.

NEW PRECLINICAL MODELS TO IMPROVE HCC THERAPY
=============================================

The successful development of novel drugs is largely dependent on the availability of suitable and predictive preclinical models. Besides the specific biochemical (cell-free) inhibition of a distinct target, novel compounds need to prove their potency in various *in vitro* and *in vivo* model systems before entering human clinical trials.

In the past, high throughput screening was performed on 2D cultures using immortalized cell lines. Although this approach allowed screening large numbers of cell lines, it lacks the complex interaction of different cell types and matrix structures within real tissue. Consequently, more complex 3D culture systems were established, also from primary human cancer samples, that also contain components of extracellular matrix and additional cell types as fibroblasts\[[@B85],[@B86]\]. Recently, spheroids and organoids that mimic organ structure and aggressiveness of human HCC have been established as tools for drug sensitivity screening\[[@B87],[@B88]\]. To reflect the genetic heterogeneity of human cancers, mixtures of barcoded tumor cell lines can be subjected to high throughput screening. This technology secures homogeneous drug exposure to genetically different cell types at the same time and was shown to identify responders and non-responders to specific treatments as well as to create new biomarker hypotheses\[[@B89]\].

Precision-cut liver slices represent an interesting *ex vivo* model system for drug development. Complex tissue architecture is preserved and the model allows to investigate different pathophysiologic conditions and drug testing on primary human tissue samples\[[@B90],[@B91]\].

Animal models, however, still represent standard models for early drug development approaches. As HCC usually develops on the background of chronic underlying liver diseases associated with chronic inflammation, viral infection or fibrotic remodeling, and clear oncogenic driver mutations have not been identified yet, finding suitable and appropriate models still remains an urgent task. An ideal model would therefore in parallel describe the underlying liver disease and tumor development. The increasing role of immunotherapies in HCC also urgently warrants the development of respective immunocompetent models (Table [4](#T4){ref-type="table"})\[[@B92]\].

###### 

Available techniques for induction of hepatocellular carcinoma in relation to temporal and technical aspects as well as major advantages and disadvantages (summarized from\[[@B92]\])

  **Method and specification**                                                        **Time to HCC** **short (+) to long (+++)**                                                                      **Technical efforts** **low (+) to high (+++)**   **Major "Pros" (+) *vs* "Contras" (-)**
  ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------------------------
  Chemotoxic agents linked models                                                                                                                                                                                                                        
  Diethylnitrosamine                                                                  ++                                                                                                               \+                                                (+) good combination options with other methods
  9,10-dimethyl-1,2-benzanthracene                                                    (-) time to HCC not easily predictable                                                                                                                             
  Direct implantation of tumor cells or tissue                                                                                                                                                                                                           
  Heterotopic/orthotopic                                                              \+                                                                                                               +/++                                              (+) heterotopic xenografts are often and easily done
  (+) syngeneic orthotopic models better reflect the natural liver microenvironment                                                                                                                                                                      
  Syngeneic/xenografts                                                                (-) xenografts need immunocompromised mice                                                                                                                         
  (-) orthotopic tumor implants need surgical and imaging experience                                                                                                                                                                                     
  Genetically engineered mouse models                                                                                                                                                                                                                    
  Mouse embryo manipulation                                                           ++/+++                                                                                                           +++                                               (+) hepatocarcinogenesis can be analyzed stepwise
  Cre-Lox recombination                                                               (-) effects of manipulated gene(s) could have heterogeneous latency and genetic penetrance                                                                         
  Hydrodynamic injection                                                                                                                                                                                                                                 
  CRISPR-Cas9                                                                                                                                                                                                                                            
  Humanized mouse models                                                                                                                                                                                                                                 
  Immunologically humanized mice                                                      +++                                                                                                              +++                                               (+) immunotherapeutical issues can be studied based on human cell lines in mice
  Genetically humanized mice                                                          (-) establishment difficult due to engraftment failure and development of stable stem cell-derived hepatocytes                                                     

HCC: Hepatocellular carcinoma.

The subcutaneous implantation of HCC cell lines was extensively used in the past and still has value when using primary cell lines or tissue explants (patient-derived xenograft models). These models are relatively easy to handle and provide an easy readout of tumor growth by caliper measurement. Orthotopic implantation reflects the primary site of tumor formation and crossplay with liver matrix and cells but requires surgical expertise and more advanced imaging technologies to monitor tumor growth. Both systems need immunodeficient mice unless syngeneic murine tumors are used. This limits the application of those models for studying immunotherapy approaches.

As human HCC can also develop upon chronic exposure to toxic agents, chemical induction in mice using diethylnitrosamine (DEN) has been established as a standard method but is limited by high variability of tumor formation and time to develop tumors\[[@B93]\]. Yet, chemical models can easily be combined with other approaches (*e.g*., fibrosis induction, NASH models, alcohol) and thus provide an option for rapid evaluation of novel drugs under distinct pathophysiologic conditions\[[@B94]-[@B97]\].

Genetically engineered mice (GEM) are useful tools to study the contribution and effects of individual genes on HCC pathogenesis. They are technically more demanding and may have a longer latency period than other models. With the option of targeted knock-in and knock-out systems and combinations of those approaches, distinct molecular backgrounds can be analyzed. As today no clear single oncogenic driver for HCC development has been identified, several GEM models have been established as useful tools, *e.g*., p53-deficient\[[@B98]\] mice or mice overexpressing MYC\[[@B99]\] or WNT pathway components\[[@B100],[@B101]\]. The option to study HBV and HCV transgenic mice is of special interest. We have shown previously that dependent on the host genetic background, ER stress pathways can be activated that are known to lead to cellular stress and chronic inflammation and that are involved in fibrogenesis and ultimately also HCC pathogenesis\[[@B102],[@B103]\].

As outlined above, HCC commonly develops on the basis of an underlying chronic liver disease. Therefore, specific liver disease models are of very high relevance to study HCC pathogenesis and explore new therapeutic options\[[@B92]\]. Several small animal models for the development of liver fibrosis and cirrhosis are currently established. Application of carbon tetrachloride (CCl~4~) or thioacetamide (in combination with ethanol)\[[@B104]\] leads to rapid fibrosis development and acute inflammation\[[@B105]\]. While easy to handle, these models can be combined with GEM or orthotopic transplantation models and provide a good tool to study tumor cells with a fibrotic microenvironment.

Although less clear in its pathogenesis for HCC, the increasing prevalence of metabolic liver diseases associated with diabetes mellitus, adipositas, hyperlipidemia, hypertriglyceridemia and metabolic syndrome puts models for NAFLD/NASH in the focus of today's research models\[[@B106]-[@B108]\]. NAFLD and NASH can easily be induced by dietary models, *e.g*., using a high-fat (HFD), high-cholesterol (HCD), high-fructose or methionine and choline-deficient (MCD) diets or combinations of those classical inducers\[[@B109]\]. Yet, dietary models are often limited by not completely following the human course of disease, *e.g*., lacking HCC formation for high-fat diet or lacking obesity for the MCD diet. Therefore, models have been further refined by combining the dietary stimulus with distinct genetic models like PTEN-deficient mice, MC4R (melanocortin 4 receptor) or ALR (augmenter of liver regeneration) knockouts that reliably lead to HCC formation in 60% to 100% after approximately one year\[[@B110]\]. Recently, it was shown that HFD and HCD triggers liver cancer formation in an ApoE/LDL-receptor double knockout mouse, linking metabolic stress and athe-rosclerosis to HCC formation\[[@B111]\].

CONCLUSION
==========

Integrative and comprehensive molecular and genomic analyses could classify hepatocellular carcinoma on the basis of landscapes of genetic and molecular signatures (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) which could then lead to the identification of predictive biomarkers for novel treatment options and then impact HCC trial design and patient outcome. Consequently, all HCCs should be biopsied and specimen should be intensively investigated applying "omics"-technologies for real precision medicine approaches. Furthermore, the biological roles of the identified driver genes in HCC must be analyzed in the deeper integration of inter- and intratumoral, interpatient, and inter-ethnic tumor heterogeneity in more detail. Deeper knowledge about those drivers is urgently needed, as the underlying pathogenesis of HCC is complex and currently shifting from chronic viral infections to more metabolically driven tumorigenesis as seen in NASH. As inflammation seems to be a common ground for HCC development, it is not surprising that immune checkpoint inhibitors are moving into first line therapy setting and it is expected that this compound class will also significantly shift the therapeutic landscape in HCC soon. Therefore, tumor models with complex genetically engineering are an essential drug development and technology transfer tool closing the gap between *in vitro* experiments and intensive clinical trials in future (Table [4](#T4){ref-type="table"}). Finally, artificial intelligence and machine learning could essentially help to analyze, to classify and to interpret the dramatically increasing and high-dimensional amount of transcriptomic, genomic, epigenomic, metabolic, proteomic and imaging data in HCC\[[@B112]-[@B114]\]. The desirable aims of such approaches will be to (1) identify cancer drug targets, (2) predict anticancer sen-sitivity, toxicity and cancer resistance, and (3) give robust recommendations for therapeutic strategies in the future\[[@B115],[@B116]\].

Overall, the better understanding of the molecular pathogenesis of HCC allows for more stringent patient selection criteria in biomarker-driven studies that can improve patient outcome.
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